The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial. Specifically, we will evaluate if the Apollo Neuro device may improve the two specific symptoms highest ranked by patients as affecting qualify of life (fatigue, Raynaud phenomenon) as co-primary outcomes.
Systemic sclerosis (SSc) is a multisystem autoimmune disease that is characterized by progressive vasculopathy, excessive fibrosis, and immune system activation. Fatigue in SSc is common and greatly impacts quality of life: The prevalence of fatigue in SSc patients is significantly higher than the general population. Raynaud phenomenon (RP) in SSc is not only the most common SSc manifestation, affecting nearly all but is often the earliest SSc symptom. SSc-RP is the highest ranked SSc-related symptom affecting quality of life, and is a major cause of SSc-related morbidity. There are currently no approved medications to treat RP, SSc-associated RP phenomenon or fatigue in SSc. Thus, a non-pharmacologic intervention has the potential to provide SSc patients with a new treatment modality without common limiting side effects, and access. The Apollo wearable provides transcutaneous vibratory stimulation, and can be worn on the wrist or ankle. Goal: To recruit 160 SSc patient participants into this randomized, sham-device controlled clinical trial. Patients will be randomized 1:1 to receive the Apollo vs. sham wearable, which they will wear daily for 6 weeks. Outcome measures focus on quality-of-life. .
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
160
The Apollo Neuro wearable device is an Apple Watch-sized wearable device that delivers vibration at set frequencies , termed transcutaneous vibratory stimulation, or TVS. These low volume sound waves feel like a soothing touch to the skin (TVS) and activate touch receptors. Apollo is controlled via smartphone and worn on the wrist or ankle. The Apollo is fitted with an adjustable band, made of a durable neoprene material with polyester overlays. Participants are asked to wear it daily for a minimum time period for 6 weeks. Users can choose from different modes of vibration, with some being energizing, others relaxing.
The Apollo Neuro is an Apple Watch-sized wearable device that delivers vibration, termed transcutaneous vibratory stimulation, or TVS. The sham device is identical in appearance to the active intervention, but provides a lower frequency vibration that has no known therapeutic benefit.
DelRicht Research Center
New Orleans, Louisiana, United States
RECRUITINGUniversity of Michigan
Ann Arbor, Michigan, United States
RECRUITINGUniversity of Pittsburgh and UPMC Scleroderma Center
Pittsburgh, Pennsylvania, United States
Change in fatigue
The PROMIS® (Patient-Reported Outcomes Measurement Information System) SF v1.0 Fatigue 13a scale. This is a13-item, patient reported measure of an individual's level of fatigue during their usual daily activities over the past week. The raw score is converted to a T-score for analysis with 50 for the mean and a standard deviation of 10.
Time frame: Baseline, 6 Weeks
Change in average weekly Raynaud attacks
Average number of weekly Raynaud attacks. Over a period of one week, patients will record their Raynaud phenomenon (RP) attack frequency via a smartphone app. The Raynaud app is usable on both Apple iPhones and Android phones.
Time frame: Baseline, 6 Weeks
Change in quality of life
The EuroQol (EQ)-5D-5L will be used. The quality-of-life assessment instrument has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a patient global assessment visual analog scale (VAS). In the EQ-5D-5L each dimension is ranked on 5 levels of severity. Full health is a score of 1 and values below zero are regarded as a state worse than death.
Time frame: baseline up to week 6
Change in Raynaud phenomenon symptom severity
The ASRAP (Assessment of Scleroderma-associated RAynaud's Phenomenon) Questionnaire Short form is a 10-item patient self-report questionnaire regarding symptoms over the last week. Raw scores are converted to T-score with a median of 50.
Time frame: baseline to week 6
Change in the Raynaud Condition Score
The Raynaud Condition Score is a patient-reported outcome of a single question regarding Raynaud severity. It is a visual analog scale with a results range of 0-100. A score of 0 is no symptoms, and 100 is severe symptoms. It is recommended by OMERACT for assessment of Raynaud phenomenon.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Vanderbilt University Medical Center
Nashville, Tennessee, United States
RECRUITINGTime frame: baseline to week 6
Change Sleep
PROMIS® Sleep disturbance short form 4a will be used. This 4-item questionnaire uses a 5-point Likert scale for responses, inquiring about symptoms over the last week. Raw scores are converted to T-scores, with a mean of 50 and SD of 10.
Time frame: change from baseline to week 6
Change in pain
We will use the PROMIS pain interference (v1.1- Short Form 4a) questionnaire which poses 4 questions regarding the last week of pain symptoms. Responses are in a 5-point likert scale from not at all to very much. Raw scores are converted to T-scores for analysis with a median of 50 and standard deviation of 10.
Time frame: baseline to week 6
Change in depression
Depression as measured by the Patient Health Questionnaire (PHQ-8). These 8 questions are responded to with a Likert scale of 0(never) up to 3 (always) with a score range of 0-27.
Time frame: change baseline to week 6
Change in Social Function
Captured using PROMIS Short Form v2.0 - Ability to Participate in Social Roles and Activities 4a. This is a 4-question survey, with respondents answering a 5-point likert scale from 'never' to 'always'. Raw scores are converted to T-scores with a mean of 50 and standard deviation of 10.
Time frame: baseline to week 6
Change in dysautonomia symptoms
Change in dysautonomia symptoms as measured with the COMPASS-31 scale. This is a 31-question instrument which includes six domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor . A higher score indicates worse autonomic function. Following appropriate weighting, this instrument provides an autonomic symptom score from 0 to 100.
Time frame: baseline to week 6
Change in pain intensity
PROMIS® Numeric Rating Scale v.1.0 - Pain Intensity 1a will be used. This is a single question inquiring about pain in the last week, rating from 0 (no pain) to 10 (worst pain).
Time frame: baseline to week 6